Selected peer-reviewed journal articles and book chapters
Knox D, Parikh V. Basal forebrain cholinergic systems as circuits through which traumatic stress disrupts emotional memory regulation. Neuroscience and Biobehavioral Reviews 2024; in press.
Duggan MR, Steinberg Z, Peterson T, Francois T-J, Parikh V. Cognitive trajectories in longitudinally trained 3xTg-AD mice. Physiology and Behavior 2024; 275: 114435.
Andalib S, Divani AA, Ayata C, Baig S, Arsava EM, Topcuoglu MA, Cacere EL, Parikh V, Desai MJ, Majid A, Girolami S, Napoli MD. Vagus nerve stimulation in ischemic stroke. Current Neurology and Neuroscience Reports 2023; 23: 947-962.
Kniffin A, Bangasser DA, Parikh V. Septohippocampal cholinergic system at the intersection of stress and cognition: New insights and translational implications. European Journal of Neuroscience 2023; in press.
Carmon H, Haley EC, Parikh V, Tronson NC, Sarter, M. Neuro-immune modulation of cholinergic signaling in an addiction vulnerability trait. eNeuro 2023; 10: ENEURO.0023-23.2023 1–16.
Khan MM, Parikh V. Prospects for neurotrophic factor-based early intervention in schizophrenia: Lessons learned from the effects of antipsychotic drugs on cognition, neurogenesis and neurotrophic factors. CNS and Neurological Disorders – Drug Targets 2023; 289-303.
Eck SR, Kokras N, Wicks B, Baltimas P, Hall A, Bendegem N, Salvatore M, Cohen S, Bergmann J, Ceretti A, Parikh V, Dalla C, Bangasser DA. Corticotropin releasing factor in the nucleus basalis of Meynert impairs attentional performance and reduces levels of glutamate and taurine in male and female rats. Neuropharmacology 2022; 221:109280.
Duggan MR, Lu A, Foster TC, Wimmer ME, Parikh V. Exosomes in age-related cognitive decline: Mechanistic insights and improving outcomes. Frontiers in Aging Neuroscience 2022; 14: 834775.
Donovan E, Avila C, Klausner S, Parikh V, Fenollar-Ferrer C, Blakely RD, Sarter M. Disrupted choline clearance and sustained acetylcholine release in vivo by a common choline transporter coding variant associated with poor attentional control in humans. The Journal of Neuroscience 2022; 42: 3426-3444.
Duggan MR, Joshi S, Strupp J, Parikh V. Chemogenetic inhibition of prefrontal projection neurons constrain top-down control of attention in young but not aged rats. Brain Structure and Function 2021; 226: 2357-2373.
Yegla B, Joshi S, Strupp J, Parikh V. Dynamic interplay of frontoparietal cholinergic innervation and cortical reorganization in the regulation of attentional capacities in aging. Neurobiology of Aging 2021; 105: 186-198.
Duggan MR, Parikh V. Microglia and modifiable life factors: Potential contributions to cognitive resilience in aging. Behavioral Brain Research 2021; 405:113207.
Duggan M, Ahooyi TM, Parikh V, Khalili K. Neuromodulation of BAG co-chaperones by HIV-1 viral proteins and H2O2: Implications for HIV-associated neurological disorders. Cell Death Discovery 2021; 7:60.
Bongiovanni A, Peer K, Carpenter RE, Ellis AS, Duggan MR, Parikh V, Wimmer ME. Aging reduces the sensitivity to the reinforcing efficacy of morphine. Neurobiology of Aging 2021; 97: 28-32.
Goldberg LR, Zeid D, Kutlu MG, Cole RD, Lallai V, Sebastian A, Albert I, Fowler C, Parikh V, Gould TJ. Paternal nicotine enhances fear memory, reduced nicotine self-administration and alters hippocampal genetic and cholinergic function subsequent generations. Addiction Biology 2021; 26: e12859.
Parikh V, Bangasser DA. Cholinergic signaling modes and cognitive control of attention. In: Current Topics in Behavioral Neuroscience (Shoaib M and Wallace T, eds), 2020, Vol 45, PP 71-87, Springer, Berlin, Heidelberg.
Chawla PA, Parikh V. Alzheimer’s disease: The unwanted companion of the elderly. CNS and Neurological Disorders – Drug Targets 2020; 19: 646-647.
Eck S, Xu S-J, Telenson A, Duggan MR, Cole RD, Wicks B, Bergmann J, Lefebo H, Shore M, Shepard K, Akins M, Parikh V, Heller EA, Bangasser DA. Stress regulation of sustained attention and the cholinergic attention system. Biological Psychiatry 2020; 88: 566-575.
Cole RD, Zimmerman M, Kutlu MG, Matchanova A, Gould TJ, Parikh V. Cognitive rigidity and BDNF-mediated frontostriatal glutamate neuroadaptations during spontaneous nicotine withdrawal. Neuropsychopharmacology 2020; 45: 866-876.
Duggan MR, Joshi S, Tan Y, Slifker M, Ross EA, Wimmer M, Parikh V. Transcriptomic changes in the prefrontal cortex of rats as a function of age and cognitive engagement. Neurobiology of Learning and Memory 2019; 163: 10735.
Wickens MM, Deutschmann AU, McGrath AG, Parikh V, Briand LA. Glutamate receptor interacting proteins act within the prefrontal cortex to blunt cocaine seeking. Neuropharmacology 2019; 157: 107672.
Koshy Cherian A, Tronson NC, Parikh V, Blakely RD, Sarter M. Repetitive mild concussion in mice with a vulnerable cholinergic system: lasting cholinergic attentional impairments and brain cytokine expression in CHT+/- mice. Behavioral Neuroscience 2019; 133: 448-459.
Cole RD, Parikh V. Nicotine dependence in schizophrenia: contributions of nicotinic acetylcholine receptors. In: Neuroscience of Nicotine (Preedy V, ed), 2019, pp 135-143, Amsterdam, Netherlands, Elsevier.
Cole RD, Wolsh C, Zimmerman M, Gould TJ, Parikh V. Adolescent and adult nicotine exposure differentially impacts oral nicotine and oral saccharin self-administration in mice. Behavioral Brain Research 2019; 359: 836-844.
Zhou L, Fisher ML, Cole RD, Gould TJ, Parikh V, Ortinski PI, Turner JR. Neuregulin 3 signaling mediates nicotine dependent synaptic plasticity in the orbital frontal cortex and cognition. Neuropsychopharmacology 2018; 43: 1343-1354.
Yegla B, Parikh V. Developmental suppression of forebrain trkA receptors and attention capacities in aging rats: A longitudinal study. Behavioral Brain Research 2017; 335: 111-121.
Koshy Cherian A, Parikh V, Wang Q, Wu Q, Mao-Draayer Y, Blakely RD, Sarter M. Hemicholinium-3 sensitive choline transport in human T lymphocytes: Evidence for use as a proxy for brain choline transporter (CHT) capacity. Neurochemistry International 2017; 108: 410-416.
Koshy Cherian A, Kucinski A, Pitchers K, Yegla B, Parikh V, Kim Y, Valuskova P, Gurnani S, Lindsley CW, Blakely RD, Lindsley CW, Sarter M. Unresponsive choline transporter as a trait neuromarker and a causal mediator of bottom-up attentional biases. The Journal of Neuroscience 2017; 37: 2947-2959.
Wicks B, Waxler DE, White K, Duncan N, Bergmann J, Cole RD, Parikh V, Bangasser DA. Method for testing sustained attention in touchscreen operant chambers in rats. Journal of Neuroscience Methods 2017; 277: 30-37.
Parikh V, Naughton SX, Yegla B, Guzman D. Impact of partial dopamine depletion on cognitive flexibility in BDNF heterozygous mice. Psychopharmacology 2016; 233: 1361-1375.
Sarter M, Lustig C, Berry AS, Gritton H, Howe WM, Parikh V. What do phasic cholinergic signals do? Neurobiology of Learning and Memory, 2016; 130: 135-141.
Parikh V, Kutlu M, Gould TJ. nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: current trends and perspectives. Schizophrenia Research 2016; 171: 1-15.
Cole RD, Kawasumi Y, Parikh V, Bangasser DA. Corticotropin releasing factor impairs sustained attention in male and female rats. Behavioral Brain Research 2016; 296: 30-34.
Parikh V, Cole RD, Patel PJ, Poole RL, Gould TJ. Cognitive control deficits during mecamylamine-precipitated withdrawal in mice: Possible links to frontostriatal BDNF imbalance. Neurobiology of Learning and Memory 2016; 128: 110-116.
Cole RD, Poole RL, Guzman D, Gould TJ, Parikh V. Contributions of β2 subunit-containing nAChRs to chronic nicotine-induced alterations in cognitive flexibility in mice. Psychopharmacology 2015; 232: 1207-1217.
Kutlu M, Parikh V, Gould TJ. Nicotine addiction and psychiatric disorders. International Review of Neurobiology 2015; 124: 171-208.
Yegla B, Parikh V. Rejuvenating procholinergic treatments for cognition enhancement in AD: current challenges and future prospects. Frontiers in Systems Neuroscience 2015; 8: 254.
Parikh V, Bernard CS, Naughton SX, Yegla B. Interactions between Aβ oligomers and presynaptic cholinergic signaling: age-dependent effects on attentional capacities. Behavioral Brain Research 2014; 274: 30-42.
Parikh V, Naughton SX, Shi X, Kelley LK, Yegla B, Rawls SM, Unterwald EM. Cocaine- induced neuroadaptations in striatal glutamate signaling and behavioral sensitization. Neurochemistry International 2014; 75:54-65.
Yegla B, Parikh V. Effect of sustained ProNGF blockade on attentional capacities in aged rats with compromised cholinergic system. Neuroscience 2014; 261: 118-132.
D’Amore DE, Tracy BA, Parikh V. Exogenous BDNF facilitates strategy shifting by modulating glutamate dynamics in the dorsal striatum. Neuropharmacology 2013; 75:312-323.
Ortega LA, Tracy BA, Gould TJ, Parikh V. Effect of chronic low- and high-dose nicotine on cognitive flexibility in C57BL/6J mice. Behavioral Brain Research 2013; 238: 134-145.
Parikh V, Howe WM, Welchko R, Naughton SX, Han D, D’Amore DE, Turner DL, Sarter M. Diminished trkA receptor signaling reveals cholinergic-attentional vulnerability of aging. European Journal of Neuroscience 2013; 37:278-293.
Parikh V, St. Peters M, Blakely RD, Sarter M. The presynaptic choline transporter imposes limits on sustained cortical acetylcholine release and attention. The Journal of Neuroscience 2013; 33:2326-2337.
Parikh V, Sarter M. Regulation and functions of forebrain cholinergic systems: new insights based on rapid detection of choline spikes using enzyme-based biosensors. In: Microelectrode Biosensors (Dale N, Marinesco S, eds), 2013, Neuromethods: Springer Protocols Vol 80, PP 257-273, Humana Press Inc., New York
Howe WM, Ji J, Parikh V, Williams S, Sarter M. Enhanced shifting from endogenous to exogenous attention by selective stimulation of α4β2* nAChRs: underlying cholinergic mechanisms. Neuropsychopharmacology 2010; 35:1391-1401.
Parikh V, Sarter M. Cognitive decline in laboratory animals: models, measures, and validity. In: Encyclopedia of Behavioral Neuroscience (Koob G, Thompson RF, LeMoal M, eds), 2010, Vol 1, pp 294-301, Amsterdam, Netherlands: Elsevier.
Parikh V, Ji J, Decker MW, Sarter M. Prefrontal β2 subunit-containing and α7 nAChRs differentially control glutamatergic and cholinergic signaling. The Journal of Neuroscience 2010; 30:3518-3530.
Sarter M, Parikh V, Howe MW. nAChR-agonist induced cognition enhancement: integration of cognitive and neuronal mechanisms. Biochemical Pharmacology 2009; 78: 658-667.
Sarter M, Parikh V, Howe, MW. Phasic acetylcholine and the volume transmission hypothesis: time to move on. Nature Reviews Neuroscience 2009; 10: 383-390.
Parikh V, Man K, Decker MW, Sarter M. Glutamatergic contributions to nAChR agonist-evoked cholinergic transients in the prefrontal cortex. The Journal of Neuroscience 2008; 28: 3769-3680.
Parikh V, Sarter M. Cholinergic mediation of attention: the contribution of phasic versus tonic components of prefrontal cholinergic activity. Annals of the New York Academy of Sciences 2008; 1129: 225-235.
Parikh V, Kozak R, Martinez V, Sarter M. Prefrontal acetylcholine release controls cue detection on multiple time scales. Neuron 2007; 56: 141-54.
Terry AV, Parikh V, Gearhart DA, Pillai A, Nasrallah HA, Mahadik SP. Time dependent effects of haloperidol and ziprasidone on nerve growth factor, cholinergic neurons, and spatial learning in rats. Journal of Pharmacology and Experimental Therapeutics 2006; 318: 709-724.
Hernandez CM, Gearhart DA, Parikh V, Hohnadel EJ, Davis LW, Middlemore ML, Waller JL, Terry AV. Comparison of galantamine and donepezil for effects on nerve growth factor, cholinergic markers and memory performance in aged rats. Journal of Pharmacology and Experimental Therapeutics 2006; 316:679-694.
Martinez V, Parikh V, Sarter M. Sensitized attentional impairments and Fos-immunoreactive cholinergic neurons in the basal forebrain following administration of escalating doses of amphetamine. Biological Psychiatry 2005; 57:1138-1146.
Sarter M, Parikh V. Choline transporters, cholinergic transmission and cognition. Nature Reviews Neuroscience 2005; 6:48-56.
Parikh V, Evans DR, Khan MM, Mahadik SP. Nerve growth factor levels in never-medicated first-episode psychotic patients and medicated chronic schizophrenic patients. Schizophrenia Research 2003; 60:117-123.